« Return to News | Technology Solutions | Study Conduct

EP Clinical Trials links EudraCT and ClinicalTrials.gov

Tuesday, November 15, 2011 04:04 PM

London-based EvaluatePharma, a source for life science sector analysis, has launched its new clinical trial intelligence service, EP Clinical Trials. By linking EudraCT and ClinicalTrials.gov records, the new service delivers a unique synthesis of clinical trials information.

"Currently 52% (15,900+ trial records) of the EudraCT clinical trial data, originally released in March 2011, has been made public, and we have successfully linked half of this data via NCT-ID reference number to ClinicalTrials.gov records," said Anthony Raeside, head of research at EvaluatePharma. "Our goal is to continue to make the data as meaningful and valuable as possible by indexing, linking, and revealing previously un-recognized synergies between the public clinical trial directories."

By linking the two leading sources of clinical trial records, additional information benefits include: enrollment numbers available for each E.U. country, trials identified for orphan indications, standardized technology for investigational drugs disclosed, standardized pharmaceutical form such as transdermal patch and the ability to identify commercial company trials unique to the EudraCT site.

EP Clinical Trials is updated daily and also provides mapped data such as biopharmaceutical company and product information, peak and historical sales, indication, top level deal information and custom data alerts and commentary and analysis.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013
Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings
Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving
Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.